Compare Crispr Therapeutics AG (CRSP) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs VNET Group Inc — how do they compare? Crispr Therapeutics AG trades at $53.67 (market cap $4.88B), while VNET Group Inc trades at $5.49 (market cap $1.47B). The key difference: Crispr Therapeutics AG is far larger — about 3.3× VNET Group Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and VNET Group Inc for 16 Days on average.
| CRSP | VNET | |
|---|---|---|
Market Cap | $4.88B | $1.47B |
Volume | 2,861,747 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $74.92 | $14.03 |
52-Week Low | $44.34 | $5.13 |
Typical Hold Time | 77 Days | 16 Days |
Enterprise Value | $3.30B | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
VNET trades at $5.42, up 0.56% today but near a 52-week low. Technicals are bearish with moving averages signaling sell, while fundamentals show revenue growth to $9.95B in 2025 but net losses of $256.77M. Recent news includes a strategic investment closing and a new low, reflecting mixed sentiment amid high institutional interest and negative cash flow trends.
Outlook: Strategic partnerships and AI demand offer growth, but high debt, negative margins, and bearish technicals pose significant risks. Analyst consensus is moderately bullish (62.5% buy), yet profitability challenges and leverage require caution for investors seeking turnaround potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
